Lv1
78 积分 2024-01-22 加入
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
1个月前
已完结
Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial
1个月前
已完结
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
1个月前
已完结
Rearranged during transfection (RET) lung cancer – Update on targeted therapies
1个月前
已完结
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
1个月前
已完结
Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database
2个月前
已完结
Reversing “Flip-Flop” Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib
2个月前
已完结
Discovery of Piperazine-Amide Derivatives as Highly Potent and Selective RET Inhibitors
3个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
3个月前
已完结
Adagrasib for KRASG12C mutated advanced non-small-cell lung cancer
3个月前
已完结
皖公网安备34019202002308
